Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.

被引：73

作者：

Antonia, Scott Joseph

Gettinger, Scott N.

Chow, Laura Quan Man

Juergens, Rosalyn A.

Borghaei, Hossein

Shen, Yun

Harbison, Christopher

Chen, Allen C.

Ready, Neal

Rizvi, Naiyer A.

机构：

[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Univ Washington, Seattle, WA 98195 USA

[4] Juravinski Canc Ctr, Hamilton, ON, Canada

[5] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[6] Bristol Myers Squibb Co, Princeton, NJ USA

[7] Duke Univ, Med Ctr, Durham, NC USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.8023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

8023

引用

页数：1